The earnings call highlights Bio-Rad's strong financial performance, successful acquisitions and product launches, and improved cash flow, but also notes challenges in diagnostics sales, gross margin, and market softness in biotech and academic sectors.

Company Guidance -

Q3 2025

During the Bio-Rad Second Quarter 2025 Results Conference Call, the company provided updated guidance and insights into its performance metrics. Bio-Rad reported net sales of approximately $652 million for Q2 2025, marking a 2.1% increase from $638 million in Q2 2024. The non-GAAP operating margin for the quarter was 13.6%, down from 16.7% in the previous year due to a decrease in gross margin. The company saw strong performance in its process chromatography products, driving a double-digit growth expectation for the year. The Droplet Digital PCR (ddPCR) portfolio also showed promising developments, with a mid-single digit growth forecast for 2025, aided by the acquisition of Stilla Technologies. Bio-Rad raised its full-year guidance, anticipating a flat to 1% growth in total currency-neutral revenue. Additionally, the company experienced a reduced tariff headwind, now projected at 30 to 40 basis points against operating margin, leading to an improved gross margin outlook of 53.5% to 54.5% for the year.

Revenue and Operating Margin Exceed Expectations

Bio-Rad's second quarter 2025 results exceeded consensus expectations with revenue reaching $652 million, a 2.1% increase from Q2 2024, and operating margin outperforming due to disciplined cost control.

Process Chromatography Growth

Process chromatography products experienced strong double-digit growth, with an increase from high single-digit to low double-digit growth expected for 2025.

Successful Acquisition and Product Launch

Bio-Rad completed the acquisition of Stilla Technologies and launched the QX Continuum and QX700 Series ddPCR instruments, enhancing their Droplet Digital PCR portfolio.

Positive Clinical Developments

Incyte Molecular Diagnostics announced positive clinical data for its ddPCR assay in kidney transplant monitoring, and Genoscopy's ColoSense test was included in the NCCN guidelines.

Improved Free Cash Flow

Free cash flow reached $71 million in Q2 2025, up from $55 million in Q2 2024, with a year-to-date free cash flow to non-GAAP net income conversion ratio of 117%.

Increased Guidance for 2025

Bio-Rad raised its 2025 full-year guidance, expecting currency-neutral revenue to range from flat to 1% growth, with improved outlooks for ddPCR and process chromatography.

Bio-Rad Laboratories (BIO) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

BIO Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 23, 2025	2025 (Q3)	1.97 / -	2.01	―	―	―
Jul 31, 2025	2025 (Q2)	1.73 / 2.61	3.11	-16.08% (-0.50)
May 01, 2025	2025 (Q1)	1.81 / 2.54	2.29	10.92% (+0.25)	―
Feb 13, 2025	2024 (Q4)	2.87 / 2.90	3.1	-6.45% (-0.20)	―
Oct 30, 2024	2024 (Q3)	1.16 / 2.01	2.33	-13.73% (-0.32)	―
Aug 01, 2024	2024 (Q2)	2.02 / 3.11	3	3.67% (+0.11)	―
May 07, 2024	2024 (Q1)	2.15 / 2.29	3.34	-31.44% (-1.05)	―
Feb 15, 2024	2023 (Q4)	2.82 / 3.10	3.31	-6.34% (-0.21)	―
Oct 26, 2023	2023 (Q3)	2.78 / 2.33	2.6	-10.38% (-0.27)	―
Aug 03, 2023	2023 (Q2)	2.68 / 3.00	3.38	-11.24% (-0.38)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

BIO Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 31, 2025	$241.95	$284.60	+17.63%
May 01, 2025	$240.43	$236.34	-1.70%
Feb 13, 2025	$306.36	$277.16	-9.53%
Oct 30, 2024	$330.58	$358.19	+8.35%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Bio-Rad Laboratories (BIO) report earnings?

Bio-Rad Laboratories (BIO) is schdueled to report earning on Oct 23, 2025, After Close (Confirmed).

What is Bio-Rad Laboratories (BIO) earnings time?

Bio-Rad Laboratories (BIO) earnings time is at Oct 23, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is BIO EPS forecast?

BIO EPS forecast for the fiscal quarter 2025 (Q3) is 1.97.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing